Which PD patients will you be implementing tavapadon?

I am excited to try this new selective D1/D5 dopamine agonist to address mild-to-moderate motor symptoms of Parkinson's disease and wearing off/motor fluctuations. Being a selective agonist at D1/D5 receptors, tavapadon has the potential for fewer side effects, such as drowsiness, nausea, and impuls...

Tavapadon will be a new-generation dopamine agonist.

It is a very specific D1/D5 agonist.

The hope based on TEMPO 1, TEMPO 2, and TEMPO 3 studies is that we will see fewer side effects than the traditional dopamine agonists of the past.

This means that there may be a shift toward using tavapadon early ...

Tavapadon, a selective D1/D5 partial agonist, demonstrated efficacy in two distinct PD populations across three Phase 3 TEMPO trials (Pahwa et al., PMID 41860533; Fernandez et al., PMID 42456682; Fernandez et al., PMID 41860544). It remains investigational and is not yet FDA-approved, but the clinic...